Clinicopathological features of pseudomyogenic hemangioendothelioma and precision therapy based on whole exome sequencing  

作　　者：Junqiang Wei Zhichao Liao Gang Zhao Nazmun Nahar Chao Zhang Jia Lu Yun Yang Jilong Yang 

机构地区：[1]Department of Bone and Soft Tissue Tumors,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,P.R.China [2]National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,P.R.China [3]Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,P.R.China [4]Department of Orthopedics,Affiliated Hospital of Chengde Medical College,Chengde,Hebei 067000,P.R.China [5]International Medical School,Tianjin Medical University,Tianjin 300061,P.R.China

出　　处：《Cancer Communications》2020年第4期197-201,共5页癌症通讯（英文）

基　　金：This work was supported by the Key Nature Science Foundation of Tianjin(grant nos.18YFZCSY00550 to Jilong Yang)。

摘　　要：Dear Editor Pseudomyogenic hemangioendothelioma(PHE)is a newly recognized subtype of hemangioendothelioma characterized by the presence of fibrohistiocytic and myoid cells arranged in a fibroma-like or dermatofibroma-like pattern[1].This rare type of tumor was first named by Hornick and Fletcher[2]and categorized as the novel soft tissue tumor classification system of the World Health Organization in 2013[3].Prior to this,it was referred to as fibroma-like variant of epithelioid sarcoma(ES)and epithelioid sarcoma-like hemangioendothelioma[4].

关 键 词：SARCOMA MYOGENIC ENDO 

分 类 号：R73[医药卫生—肿瘤]